Lakefront Biotherapeutics NV GLPGF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.08M | 7.58M | 1.05B | 74.10M | 74.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.08M | 7.58M | 1.05B | 74.10M | 74.10M |
| Cost of Revenue | 40.32M | 41.84M | 125.68M | 47.99M | 113.47M |
| Gross Profit | -26.24M | -34.26M | 922.96M | 26.11M | -39.37M |
| SG&A Expenses | 26.18M | 41.54M | 37.59M | 15.97M | 34.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.81M | -1.27M | -37.39M | -9.46M | -9.46M |
| Total Operating Expenses | 64.69M | 82.12M | 125.88M | 54.49M | 138.82M |
| Operating Income | -50.61M | -74.53M | 922.76M | 19.60M | -64.72M |
| Income Before Tax | 2.34M | 16.33M | 911.67M | -118.51M | -118.51M |
| Income Tax Expenses | 81.40K | 81.90K | 775.30K | 29.50K | 29.50K |
| Earnings from Continuing Operations | 2.26M | 16.25M | 910.89M | -118.54M | -118.54M |
| Earnings from Discontinued Operations | 191.90K | 709.00K | -399.30K | -1.47M | -1.47M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.45M | 16.96M | 910.49M | -120.02M | -120.02M |
| EBIT | -50.61M | -74.53M | 922.76M | 19.60M | -64.72M |
| EBITDA | -48.84M | -64.91M | 932.33M | 40.32M | -44.00M |
| EPS Basic | 0.04 | 0.26 | 13.82 | -1.82 | -1.82 |
| Normalized Basic EPS | -0.16 | -0.29 | 9.23 | 0.21 | -0.83 |
| EPS Diluted | 0.04 | 0.26 | 13.81 | -1.82 | -1.82 |
| Normalized Diluted EPS | -0.16 | -0.29 | 9.22 | 0.21 | -0.83 |
| Average Basic Shares Outstanding | 65.90M | 65.87M | 65.90M | 65.96M | 65.96M |
| Average Diluted Shares Outstanding | 66.04M | 65.87M | 65.92M | 65.96M | 65.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |